CDKL5 and Dravet syndrome: Ten meta-analyses [5,67,68,69,70,71,72,73,74] were conducted to evaluate the impact of KD or MAD on the proportion of seizure reduction observed in various conditions such as pediatric epilepsy, childhood epilepsy, refractory epilepsy, Lennox–Gastaut syndrome, Dravet syndrome, infantile spasms, infant epilepsy, CDKL5-related epilepsy, drug-resistant epilepsy, and Sturge–Weber syndrome (Figure 3, Supplemental Tables S1 and S3).